How does EMA look at toxicity/benefit ratios in cancer treatment

Date 11 September 2017
Event ESMO 2017 Congress
Session Are grade III / IV toxicities the only ones that matter?
Topics Complications of Treatment
Bioethics, Legal, and Economic Issues
Palliative and Supportive Care
Presenter Francesco Pignatti
Authors F. Pignatti
  • Scientific And Regulatory Management , European Medicines Agency (EMA), E14 4HB - London/GB